April 24th 2024
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial
A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.
Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.
Small Elderly CLL Population Discontinues Venetoclax/Obinutuzumab Treatment
August 24th 2023Findings from a real-world study highlight that treatment utilization, such as agents for managing tumor lysis syndrome, appears to be more intense when older patients with chronic lymphocytic leukemia initiate treatment with venetoclax plus obinutuzumab.
Cross Q&A: Real-World Use of Low-Dose Dasatinib in CML
Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.
Chronic Myeloid Leukemia: Long-Term Follow-up of Low-Dose Dasatinib
In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.
Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML
In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.
Relapsed/Refractory CLL: Key Takeaways and Ongoing Challenges
Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Safety Analysis
Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Blinatumomab Improves OS/DFS in Low-Risk, Relapsed ALL Subgroup
August 6th 2023Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.
Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia
A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.
Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial
Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.
Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Efficacy Analysis
Alan Skarbnik, MD, and Ryan Jacobs, MD, review efficacy data from the indirect comparison study of acalabrutinib versus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia.
Clinical Trials With BTK Inhibitors in Relapsed/Refractory CLL
Focused discussion on key clinical trial data behind currently available BTK inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia.
Ibrutinib/Venetoclax Appears to Reduce Clinical/Molecular Relapse in CLL
July 29th 2023The potential reduction in relapse in patients with unresectable chronic lymphocytic leukemia appears to happen regardless of minimal residual disease status 3 months post-treatment and immunoglobulin heavy-chain variable region mutational status.
Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study
A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.
Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML
Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.